Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.51
SNY's Cash to Debt is ranked lower than
60% of the 834 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.03 vs. SNY: 0.51 )
Ranked among companies with meaningful Cash to Debt only.
SNY' s 10-Year Cash to Debt Range
Min: 0.14   Max: 10.62
Current: 0.51

0.14
10.62
Equity to Asset 0.58
SNY's Equity to Asset is ranked higher than
63% of the 834 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.43 vs. SNY: 0.58 )
Ranked among companies with meaningful Equity to Asset only.
SNY' s 10-Year Equity to Asset Range
Min: 0.48   Max: 0.65
Current: 0.58

0.48
0.65
Interest Coverage 10.15
SNY's Interest Coverage is ranked higher than
66% of the 834 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. SNY: 10.15 )
Ranked among companies with meaningful Interest Coverage only.
SNY' s 10-Year Interest Coverage Range
Min: 7.88   Max: 19.65
Current: 10.15

7.88
19.65
F-Score: 7
Z-Score: 2.46
M-Score: -2.74
WACC vs ROIC
8.47%
15.61%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 17.44
SNY's Operating margin (%) is ranked higher than
83% of the 834 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.69 vs. SNY: 17.44 )
Ranked among companies with meaningful Operating margin (%) only.
SNY' s 10-Year Operating margin (%) Range
Min: 15.25   Max: 38.21
Current: 17.44

15.25
38.21
Net-margin (%) 12.34
SNY's Net-margin (%) is ranked higher than
79% of the 834 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.76 vs. SNY: 12.34 )
Ranked among companies with meaningful Net-margin (%) only.
SNY' s 10-Year Net-margin (%) Range
Min: 7.92   Max: 25.8
Current: 12.34

7.92
25.8
ROE (%) 15.78
SNY's ROE (%) is ranked higher than
81% of the 834 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.48 vs. SNY: 15.78 )
Ranked among companies with meaningful ROE (%) only.
SNY' s 10-Year ROE (%) Range
Min: 5.18   Max: 33.55
Current: 15.78

5.18
33.55
ROA (%) 9.14
SNY's ROA (%) is ranked higher than
79% of the 834 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.45 vs. SNY: 9.14 )
Ranked among companies with meaningful ROA (%) only.
SNY' s 10-Year ROA (%) Range
Min: 2.62   Max: 21.59
Current: 9.14

2.62
21.59
ROC (Joel Greenblatt) (%) 77.45
SNY's ROC (Joel Greenblatt) (%) is ranked higher than
93% of the 834 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.04 vs. SNY: 77.45 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
SNY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 31.22   Max: 145.55
Current: 77.45

31.22
145.55
Revenue Growth (3Y)(%) -1.00
SNY's Revenue Growth (3Y)(%) is ranked higher than
56% of the 834 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -5.40 vs. SNY: -1.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
SNY' s 10-Year Revenue Growth (3Y)(%) Range
Min: -1.5   Max: 27.4
Current: -1

-1.5
27.4
EBITDA Growth (3Y)(%) -4.40
SNY's EBITDA Growth (3Y)(%) is ranked higher than
63% of the 834 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -31.90 vs. SNY: -4.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
SNY' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -4.4   Max: 35.7
Current: -4.4

-4.4
35.7
EPS Growth (3Y)(%) -8.20
SNY's EPS Growth (3Y)(%) is ranked higher than
66% of the 834 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -53.60 vs. SNY: -8.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
SNY' s 10-Year EPS Growth (3Y)(%) Range
Min: -12.8   Max: 41.2
Current: -8.2

-12.8
41.2
» SNY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

SNY Guru Trades in Q2 2014

Bill Nygren 4,950,000 sh (+90.38%)
PRIMECAP Management 3,011,646 sh (+21.59%)
Sarah Ketterer 567,921 sh (+12.04%)
Charles Brandes 2,182,305 sh (+5.28%)
James Barrow 28,526,802 sh (+2.65%)
John Buckingham 20,344 sh (+1.31%)
Manning & Napier Advisors, Inc 2,961,185 sh (+1.30%)
Ken Fisher 13,079,575 sh (+1.18%)
Francis Chou 410,000 sh (unchged)
Murray Stahl 26,000 sh (unchged)
Mario Gabelli 4,500 sh (unchged)
Warren Buffett 3,905,875 sh (unchged)
John Hussman Sold Out
Dodge & Cox 43,549,909 sh (-0.26%)
HOTCHKIS & WILEY 9,772,061 sh (-0.33%)
First Eagle Investment 608,568 sh (-0.36%)
Third Avenue Management 13,402 sh (-14.67%)
Scott Black 178,985 sh (-27.57%)
NWQ Managers 2,602,503 sh (-52.34%)
» More
Q3 2014

SNY Guru Trades in Q3 2014

Manning & Napier Advisors, Inc 5,024,798 sh (+69.69%)
PRIMECAP Management 3,891,356 sh (+29.21%)
Bill Nygren 5,670,000 sh (+14.55%)
Sarah Ketterer 593,929 sh (+4.58%)
Charles Brandes 2,248,902 sh (+3.05%)
Mario Gabelli 4,580 sh (+1.78%)
John Buckingham 20,665 sh (+1.58%)
HOTCHKIS & WILEY 9,895,521 sh (+1.26%)
Ken Fisher 13,145,647 sh (+0.51%)
Warren Buffett 3,905,875 sh (unchged)
Murray Stahl 26,000 sh (unchged)
Francis Chou 410,000 sh (unchged)
Scott Black 178,410 sh (-0.32%)
Dodge & Cox 43,267,004 sh (-0.65%)
James Barrow 28,293,723 sh (-0.82%)
NWQ Managers 2,409,040 sh (-7.43%)
Third Avenue Management 12,306 sh (-8.18%)
First Eagle Investment 34,157 sh (-94.39%)
» More
Q4 2014

SNY Guru Trades in Q4 2014

David Dreman 1,102 sh (New)
Steven Cohen 1,050,000 sh (New)
NWQ Managers 2,941,923 sh (+22.12%)
HOTCHKIS & WILEY 11,692,693 sh (+18.16%)
Charles Brandes 2,571,795 sh (+14.36%)
Mario Gabelli 5,195 sh (+13.43%)
PRIMECAP Management 4,287,207 sh (+10.17%)
James Barrow 30,804,459 sh (+8.87%)
John Buckingham 22,394 sh (+8.37%)
Manning & Napier Advisors, Inc 5,433,472 sh (+8.13%)
Murray Stahl 26,295 sh (+1.13%)
Dodge & Cox 43,272,800 sh (+0.01%)
Bill Nygren 5,670,000 sh (unchged)
Francis Chou 410,000 sh (unchged)
Warren Buffett 3,905,875 sh (unchged)
First Eagle Investment 34,157 sh (unchged)
Ken Fisher 13,085,033 sh (-0.46%)
Scott Black 176,460 sh (-1.09%)
Third Avenue Management 10,704 sh (-13.02%)
Sarah Ketterer 506,796 sh (-14.67%)
» More
Q1 2015

SNY Guru Trades in Q1 2015

Paul Tudor Jones 7,598 sh (New)
NWQ Managers 3,927,517 sh (+33.50%)
John Buckingham 24,608 sh (+9.89%)
HOTCHKIS & WILEY 11,782,180 sh (+0.77%)
Charles Brandes 2,573,969 sh (+0.08%)
Francis Chou 410,000 sh (unchged)
Bill Nygren 5,670,000 sh (unchged)
Warren Buffett 3,905,875 sh (unchged)
David Dreman 1,102 sh (unchged)
Steven Cohen Sold Out
First Eagle Investment Sold Out
Third Avenue Management Sold Out
Ken Fisher 13,058,095 sh (-0.21%)
Murray Stahl 26,185 sh (-0.42%)
Scott Black 175,625 sh (-0.47%)
Dodge & Cox 43,034,073 sh (-0.55%)
James Barrow 30,225,221 sh (-1.88%)
Sarah Ketterer 477,367 sh (-5.81%)
PRIMECAP Management 3,972,907 sh (-7.33%)
Mario Gabelli 4,700 sh (-9.53%)
Manning & Napier Advisors, Inc 2,499,440 sh (-54.00%)
» More
» Details

Insider Trades

Latest Guru Trades with SNY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Sanofi

Bill Nygren Comments on Sanofi - Apr 08, 2014

Sanofi (SNY - $52)(SNY)
Sanofi is a pharmaceutical company with a good mix of durable businesses with strong growth characteristics. The company has a strong franchise in diabetes treatments, maintaining dominant market share in this rapidly growing category. Sanofi is a leading player in emerging markets, where sales growth rates are twice that of the overall pharmaceutical market. Sanofi is also a leader in vaccines, and they have a strong footprint in over-the-counter products. We think that margins and profitability should improve as the company leverages fixed R&D spending and enforces good cost controls. The company’s balance sheet has more cash than debt, and the shares sell at a substantial discount to our estimate of intrinsic value. Moreover, Sanofi has a dividend yield of 3.7%.

From Bill Nygren (Trades, Portfolio)'s Oakmark Fund first quarter 2014 commentary.

Check out Bill Nygren latest stock trades

Top Ranked Articles about Sanofi

Top Held European Stocks Highlighted by Health Care and Oil and Gas Stocks
sing the GuruFocus Aggregated Portfolio Screener you can filter results to see what companies were bought by the largest numbers of gurus over a certain period of time. By using this screener, we filtered down to see which companies based in Europe were held by the highest number of gurus. Read more...
Oakmark Funds' Bill Nygren Buys 4 New Stocks
Bill Nygren (Trades, Portfolio)’s Oakmark fund beat the S&P 500 for the first quarter with a 5% gain compared to the index’s 2% rise. In his first quarter letter, he attributed the strong quarter primarily to Forest Laboratories being acquired by Actavis Plc (ACT), and large exposure to auto-related cyclical and financials. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 28.00
SNY's P/E(ttm) is ranked higher than
55% of the 461 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 30.10 vs. SNY: 28.00 )
Ranked among companies with meaningful P/E(ttm) only.
SNY' s 10-Year P/E(ttm) Range
Min: 9.64   Max: 38.97
Current: 28

9.64
38.97
Forward P/E 7.73
SNY's Forward P/E is ranked higher than
95% of the 266 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 18.66 vs. SNY: 7.73 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 27.80
SNY's PE(NRI) is ranked higher than
60% of the 461 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 34.70 vs. SNY: 27.80 )
Ranked among companies with meaningful PE(NRI) only.
SNY' s 10-Year PE(NRI) Range
Min: 9.82   Max: 39.2
Current: 27.8

9.82
39.2
P/B 2.10
SNY's P/B is ranked higher than
62% of the 656 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.80 vs. SNY: 2.10 )
Ranked among companies with meaningful P/B only.
SNY' s 10-Year P/B Range
Min: 1.11   Max: 5.88
Current: 2.1

1.11
5.88
P/S 3.50
SNY's P/S is ranked lower than
59% of the 637 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.80 vs. SNY: 3.50 )
Ranked among companies with meaningful P/S only.
SNY' s 10-Year P/S Range
Min: 1.72   Max: 5.18
Current: 3.5

1.72
5.18
PFCF 15.60
SNY's PFCF is ranked higher than
75% of the 326 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.50 vs. SNY: 15.60 )
Ranked among companies with meaningful PFCF only.
SNY' s 10-Year PFCF Range
Min: 5.11   Max: 45
Current: 15.6

5.11
45
POCF 12.24
SNY's POCF is ranked higher than
78% of the 445 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 26.56 vs. SNY: 12.24 )
Ranked among companies with meaningful POCF only.
SNY' s 10-Year POCF Range
Min: 4.15   Max: 23.37
Current: 12.24

4.15
23.37
EV-to-EBIT 21.03
SNY's EV-to-EBIT is ranked higher than
58% of the 472 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 26.75 vs. SNY: 21.03 )
Ranked among companies with meaningful EV-to-EBIT only.
SNY' s 10-Year EV-to-EBIT Range
Min: 9.4   Max: 204.2
Current: 21.03

9.4
204.2
Shiller P/E 23.80
SNY's Shiller P/E is ranked higher than
61% of the 308 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.18 vs. SNY: 23.80 )
Ranked among companies with meaningful Shiller P/E only.
SNY' s 10-Year Shiller P/E Range
Min: 11.32   Max: 25.52
Current: 23.8

11.32
25.52
Current Ratio 1.80
SNY's Current Ratio is ranked lower than
63% of the 593 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.37 vs. SNY: 1.80 )
Ranked among companies with meaningful Current Ratio only.
SNY' s 10-Year Current Ratio Range
Min: 0.79   Max: 2.71
Current: 1.8

0.79
2.71
Quick Ratio 1.29
SNY's Quick Ratio is ranked lower than
65% of the 593 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.72 vs. SNY: 1.29 )
Ranked among companies with meaningful Quick Ratio only.
SNY' s 10-Year Quick Ratio Range
Min: 0.59   Max: 2.41
Current: 1.29

0.59
2.41
Days Inventory 156.14
SNY's Days Inventory is ranked lower than
70% of the 609 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 114.49 vs. SNY: 156.14 )
Ranked among companies with meaningful Days Inventory only.
SNY' s 10-Year Days Inventory Range
Min: 155.87   Max: 224.59
Current: 156.14

155.87
224.59
Days Sales Outstanding 74.40
SNY's Days Sales Outstanding is ranked lower than
52% of the 585 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 72.43 vs. SNY: 74.40 )
Ranked among companies with meaningful Days Sales Outstanding only.
SNY' s 10-Year Days Sales Outstanding Range
Min: 61.29   Max: 103.32
Current: 74.4

61.29
103.32

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 3.20
SNY's Dividend Yield is ranked higher than
81% of the 405 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. SNY: 3.20 )
Ranked among companies with meaningful Dividend Yield only.
SNY' s 10-Year Dividend Yield Range
Min: 1.41   Max: 5.46
Current: 3.2

1.41
5.46
Dividend Payout 0.84
SNY's Dividend Payout is ranked lower than
104% of the 340 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. SNY: 0.84 )
Ranked among companies with meaningful Dividend Payout only.
SNY' s 10-Year Dividend Payout Range
Min: 0.27   Max: 1
Current: 0.84

0.27
1
Dividend growth (3y) 3.80
SNY's Dividend growth (3y) is ranked lower than
59% of the 240 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.80 vs. SNY: 3.80 )
Ranked among companies with meaningful Dividend growth (3y) only.
SNY' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 29.6
Current: 3.8

0
29.6
Yield on cost (5-Year) 4.08
SNY's Yield on cost (5-Year) is ranked higher than
79% of the 410 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.48 vs. SNY: 4.08 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
SNY' s 10-Year Yield on cost (5-Year) Range
Min: 1.8   Max: 6.97
Current: 4.08

1.8
6.97
Share Buyback Rate -0.10
SNY's Share Buyback Rate is ranked higher than
77% of the 410 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -2.40 vs. SNY: -0.10 )
Ranked among companies with meaningful Share Buyback Rate only.
SNY' s 10-Year Share Buyback Rate Range
Min: 1.3   Max: -24.6
Current: -0.1

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 52.30
SNY's Price/Tangible Book is ranked lower than
142% of the 592 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. SNY: 52.30 )
Ranked among companies with meaningful Price/Tangible Book only.
SNY' s 10-Year Price/Tangible Book Range
Min: 6.59   Max: 2093.5
Current: 52.3

6.59
2093.5
Price/DCF (Projected) 0.60
SNY's Price/DCF (Projected) is ranked higher than
94% of the 326 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. SNY: 0.60 )
Ranked among companies with meaningful Price/DCF (Projected) only.
SNY' s 10-Year Price/DCF (Projected) Range
Min: 0.48   Max: 1.02
Current: 0.6

0.48
1.02
Price/Median PS Value 1.30
SNY's Price/Median PS Value is ranked higher than
60% of the 615 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. SNY: 1.30 )
Ranked among companies with meaningful Price/Median PS Value only.
SNY' s 10-Year Price/Median PS Value Range
Min: 0.63   Max: 2.65
Current: 1.3

0.63
2.65
Price/Peter Lynch Fair Value 5.00
SNY's Price/Peter Lynch Fair Value is ranked lower than
111% of the 160 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. SNY: 5.00 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
SNY' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.47   Max: 4.01
Current: 5

0.47
4.01
Price/Graham Number 8.00
SNY's Price/Graham Number is ranked lower than
118% of the 405 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.00 vs. SNY: 8.00 )
Ranked among companies with meaningful Price/Graham Number only.
SNY' s 10-Year Price/Graham Number Range
Min: 1.88   Max: 6.42
Current: 8

1.88
6.42
Earnings Yield (Greenblatt) 4.70
SNY's Earnings Yield (Greenblatt) is ranked higher than
68% of the 674 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.60 vs. SNY: 4.70 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
SNY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.5   Max: 10.6
Current: 4.7

0.5
10.6
Forward Rate of Return (Yacktman) 1.73
SNY's Forward Rate of Return (Yacktman) is ranked lower than
60% of the 304 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.88 vs. SNY: 1.73 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) only.
SNY' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 1.1   Max: 60.3
Current: 1.73

1.1
60.3

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Traded in other countries:0O59.UK, SAN.France, SANF.Italy, SNW2.Germany, SNW.Germany, SANNV.France, SNYNF.USA, SNYN.Mexico, SAN.Switzerland,
Sanofi was incorporated under the laws of France on April 28,1994 as a société anonyme, a form of limited liability company. It is a healthcare company, engaged in the research, development, manufacture and marketing of healthcare products. Its principal activities include Pharmaceuticals, Human Vaccines via Sanofi Pasteur, and Animal Health via Merial. It also operates through the following platforms: Emerging Markets, Diabetes Solutions, Vaccines, Consumer Health Care (CHC), Animal Health, Genzyme, and Other Innovative Products. The Pharmaceuticals segment covers research, development, production and marketing of medicines, including activities acquired with Genzyme. Sanofi's pharmaceuticals portfolio consists of flagship products, plus prescription medicines, generic medicines, and consumer health products. This segment also includes all associates and joint ventures whose activities are related to pharmaceuticals, in particular the entities majority owned by BMS. The Vaccines segment is wholly dedicated to vaccines, including research, development, production and marketing. This segment includes Sanofi Pasteur MSD joint venture with Merck & Co., Inc. in Europe. The Animal Health segment comprises the research, development, production and marketing activities of Merial, which offers medicines and vaccines for a wide variety of animal species. Its competitors include Novo Nordisk, Merck, Eli Lilly, Bristol-Myers Squibb, GlaxoSmithKline, Novartis, Shire, Pfizer, Biogen Idec, Teva and Merck Serono, Bayer, Roche, Johnson & Johnson, AstraZeneca, Boehringer-Ingelheim, Fresenius Medical Care, among others. The Company's products and manufacturing facilities are subject to significant government regulations and approvals.
» More Articles for SNY

Headlines

Articles On GuruFocus.com
Amgen’s Cholesterol Fighting Drug Receives EU Approval May 26 2015 
Dodge & Cox Stock Fund First Quarter 2015 Commentary Apr 24 2015 
Mt Stocks Apr 19 2015 
Scottrade Mar 22 2015 
Pfizer In The Process Of Making Path Breaking Vaccine Mar 18 2015 
Oh là là! Looking for Dividend Yield? Explore France Feb 27 2015 
FDA Approves Sanofi’s New Diabetes Drug Feb 27 2015 
Dodge & Cox 2014 Equity Year in Review Feb 19 2015 
The Reasons That Make Pfizer A Worthy Hold. Feb 05 2015 
Causeway Capital Global Value Equity Q4 2014 Commentary Feb 04 2015 

More From Other Websites
Retrophin Sells FDA Voucher to Sanofi May 27 2015
Retrophin Agrees to Sell Priority Review Voucher to Sanofi May 27 2015
Genzyme Commemorates World MS Day with Awareness and Educational Events Globally May 27 2015
Sanofi Appoints Suresh Kumar to the Executive Committee and Executive Vice President, External... May 26 2015
Genzyme to Present Aubagio® (teriflunomide) and Lemtrada® (alemtuzumab) Data at CMSC May 26 2015
NeuroVive Asia Signs Collaboration Agreement with Sanofi for the Development and Commercialization... May 26 2015
Fight over hot new cholesterol drugs may be won in milligrams May 26 2015
Prince Edward Island funds treatment with AUBAGIO(TM) for Relapsing Remitting Multiple Sclerosis May 25 2015
Sanofi’s Global Head for Prostate Drug, Zhen Su, Leaves Company May 22 2015
​In Massachusetts, biotech firms account for a lot of value but few jobs May 22 2015
Amgen first to win EU backing for new kind of cholesterol drug May 22 2015
Amgen first to win EU backing for new kind of cholesterol drug May 22 2015
3 Top IBD 50 Stocks Hit New All-Time Highs May 21 2015
Regeneron-Sanofi's Sarilumab Meets Endpoints in Phase III - Analyst Blog May 21 2015
Sanofi and Regeneron Announce Positive Topline Results from Phase 3 Studies with Sarilumab in... May 21 2015
Regeneron and Sanofi Announce Positive Topline Results from Phase 3 Studies with Sarilumab in... May 21 2015
Genzyme’s Announces Launch of Expression of Hope III Art Exhibit May 20 2015
Orexigen CEO Pledged To Keep Data Secret, But Not From Himself May 20 2015
Regeneron/Sanofi Announce Positive Data on Dupilumab - Analyst Blog May 19 2015
MannKind stock jumps on positive report about inhaled insulin May 19 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK